Publications:95
Jose M Silva, PhD
About Me
Language
English
Position
PROFESSOR | Pathology, Molecular and Cell Based Medicine, PROFESSOR | Graduate Education, PROFESSOR | Oncological Sciences
Research Topics
Cancer, Cancer Genetics, Tumorigenesis
Multi-Disciplinary Training Areas
Cancer Biology [CAB]
Education
BSc, Complutense University of Madrid, Spain
PhD, Autonoma University of Madrid, Spain
PostDoc, Cold Spring Harbor Laboratory, NY
Senior Fellow, Cold Spring Harbor Laboratory, NY
Assistant Professor of Pathology, Columbia University Medical School
Adjunct Faculty, Columbia University Medical School
Research
Updated October-2015 -We are looking for a molecular cell biologist with experience in breast cancer research. Previous experience in genetic manipulation of cellular models, basic biochemistry and mouse models of breast cancer will be beneficial. -Applicants must have shown research abilities and capabilities to perform collaborative project within a team, and possess good written and verbal communication skills in English. Applicants must have a Ph.D. and evidence of research productivity. Please send your C.V., contact information for two references, and a brief motivation letter including a summary of research experience to: Jose M. Silva; E-mail:jose.silva@mssm.edu
Publications
Selected Publications
- miR-424(322)<sup>~</sup>503 impairs colon cancer progression driven by PTEN deficiency. Maria Vidal-Sabanés, Núria Bonifaci, Raúl Navaridas, Joaquim EGEA, Mario Encinas, Ruth Rodriguez-Barrueco, Jose M. Silva, Xavier Matias-Guiu, Jordi Tarragona, David Llobet-Navas, Xavier Dolcet. Cell Death and Disease
- Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)<sup>~</sup>503. Maria Vidal-Sabanés, Núria Bonifaci, Raúl Navaridas, Joaquim Egea, Mario Encinas, Ruth Rodriguez-Barrueco, Jose M. Silva, Xavier Matias-Guiu, David Llobet-Navas, Xavier Dolcet. Cell Death and Disease
- Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor. Jose Silva, Jiyang Yu, Kevin Kalinsky. Nature Cancer
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Silva has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.